1 min read.Updated: 01 Apr 2021, 12:05 AM ISTLeroy Leo
Bharat Biotech can reapply for the certification of its facilities after it completes the remediation process
Brazil’s drug regulator Anvisa has rejected Bharat Biotech International’s application for supplying Covaxin in the country after an inspection of the company’s facility at Hyderabad in March found violations of norms for good manufacturing practices.
Recommended For You
Select your Category
Internet Not Available
Wait for it…
Log in to our website to save your bookmarks. It'll just take a moment.